“Cannabinoid” is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or happen endogenously. While cannabinoids interact largely at the level of the at the moment recognized cannabinoid receptors, they may have cross reactivity, such as at opioid receptors. Individuals with malignant illness represent a cohort inside well being care that have some of the greatest unmet desires regardless of the availability of a plethora of guideline-driven illness-modulating treatment options and discomfort and symptom management choices. Cannabinoid therapies are varied and versatile, and can be provided as pharmaceuticals (nabilone, dronabinol, and nabiximols), dried botanical material, and edible organic oils infused with cannabis extracts. Cannabinoid therapy regimens can be inventive, involving combinations of all of the aforementioned modalities. Individuals with malignant illness, at all points of their illness trajectory, could be candidates for cannabinoid therapies no matter whether as monotherapies or as adjuvants. The most studied and established roles for cannabinoid therapies involve discomfort, chemotherapy-induced nausea and vomiting, and anorexia. Furthermore, offered their breadth of activity, cannabinoids could be made use of to concurrently optimize the management of many symptoms, thereby lowering general polypharmacy. The use of cannabinoid therapies could be powerful in enhancing top quality of life and possibly modifying malignancy by virtue of direct effects and in enhancing compliance or adherence with illness-modulating treatment options such as chemotherapy and radiation therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 28050136 PMCID: PMC5176373 DOI: 10.3747/co.23.3487
Maida V1, Daeninck PJtwo.